An analyst named the drug developer a top pick. Also, Pharmasset said its board approved a 2-for-1 stock split. Citi analyst Yaron Werber said Pharmasset’s hepatitis C drug candidate will become part of the backbone for treatments for the disease. The New Jersey company has no products on the market. It is running midstage clinical trials of the drug and in June said it was expanding one study.